Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $12.34 on 5/22/24 after a major increase of 16.2%. Moreover, this advance was accompanied by exceptionally high trading volume at 248% of normal. The stock has declined -5.7% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CDTX is expected to continue to be Value Creation neutral.
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment